Answers are grounded in this paper and cite their sources.
Multiple prodrug strategies have been developed to deliver nucleoside monophosphates (NMPs) and thereby overcome the initial kinase-mediated intracellular phosphorylation of nucleoside analogues (NAs), a major bottleneck in their activation. However, some NAs are limited by a second and/or third slow and inefficient phosphorylation step, which can lead to accumulation of mono- and diphosphate intermediates with associated toxicity. In addition, the metabolic pathways leading to the formation of the active nucleoside triphosphates remain poorly characterised for many reported analogues. Consequently, di- and triphosphate prodrug strategies for NAs have gained increasing attention in recent years. Here, we provide a comprehensive overview of the current approaches for development of these higher phosphorylated nucleotide analogues, including their activation pathways in different media, biological activity, synthetic methodologies, and their applicability across a broad range of NAs. Taken together, this review highlights both the potential of NDP and NTP prodrug strategies and the challenges associated with their development, providing a framework to guide future advances in their rational design and broader application.
No takes yet. Share an insight, caveat, or question.
Serpi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: